首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1747034

日本生物製藥市場報告（按適應症（自體免疫疾病、腫瘤學、代謝紊亂等）、類別（重組蛋白、單株抗體、純化蛋白）和地區分類，2025 年至 2033 年）

Japan Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 120 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本生物製藥市場規模達235億美元。展望未來， IMARC Group預計到2033年，市場規模將達到358億美元，2025-2033年期間的複合年成長率（CAGR）為4.56%。市場成長主要源自於幾個關鍵因素，包括客製化藥物需求的不斷成長、慢性病和生活方式相關疾病發病率的上升，以及生物技術的快速進步，尤其是在基因工程和重組DNA技術等領域。

生物製藥，也稱為生物製劑，屬於源自生物來源的一類藥物。這些藥物是透過生物技術製程利用細菌、酵母或哺乳動物細胞等活體生物體製造的。與傳統的化學合成小分子藥物相比，生物製藥的特徵是其分子結構龐大且複雜，這使得它們能夠與體內的生物靶點進行高度精確的相互作用。生物製藥比傳統藥物具有許多優勢。它們的作用通常具有顯著的特異性，通常靶向特定的受體或分子。這種特異性通常可以提高療效並減少不良副作用。此外，生物製藥可望治療那些傳統藥物難以攻克的疾病。

日本生物製藥市場趨勢：

在日本，多種因素推動了市場的大幅成長。首先，個人化醫療的需求顯著成長，這是一個重要的促進因素。此外，生物製藥在治療癌症、糖尿病、牛皮癬和類風濕性關節炎等疾病方面的應用日益廣泛，也是推動這一成長的另一個關鍵因素。此外，公眾對生物製藥的有效性和可近性的認知不斷提高，進一步推動了區域市場的發展。此外，人們更重視罕見疾病的治療和孤兒藥的開發，這也推動了市場的成長。這些罕見疾病通常患者人數較少，存在著巨大的未滿足的醫療需求。此外，政府和監管機構推出了激勵措施並簡化了監管流程，以鼓勵開發針對這些疾病的療法，這也是另一個重要的成長誘因。此外，生物製藥公司正在積極投資研發，以開發針對罕見疾病的孤兒藥。這種方法不僅滿足了關鍵的醫療需求，也為預測期內的市場擴張創造了機會。

日本生物製藥市場細分：

指示見解：

自體免疫疾病
腫瘤學
代謝紊亂
其他

課堂見解：

重組蛋白
單株抗體
純化蛋白質

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本生物製藥市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本生物製藥市場有何影響？
日本生物製藥市場依適應症分類是怎樣的？
日本生物製藥市場依類別分類是怎樣的？
日本生物製藥市場的價值鏈分為哪些階段？
日本生物製藥的關鍵促進因素和挑戰是什麼？
日本生物製藥市場的結構是怎麼樣的？主要參與者是誰？
日本生物製藥市場的競爭程度如何？

本報告回答的關鍵問題：

日本生物製藥市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本生物製藥市場有何影響？
日本生物製藥市場依適應症分類是怎樣的？
日本生物製藥市場依類別分類是怎樣的？
日本生物製藥市場的價值鏈分為哪些階段？
日本生物製藥的關鍵促進因素和挑戰是什麼？
日本生物製藥市場的結構是怎麼樣的？主要參與者是誰？
日本生物製藥市場的競爭程度如何？

Japan biopharmaceutical market size reached USD 23.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 35.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.56% during 2025-2033. The market is experiencing growth due to several key factors, including an increasing need for customized medicines, the rising incidence of chronic and lifestyle-related illnesses, and rapid advancements in biotechnology, particularly in areas like genetic engineering and recombinant DNA technology.

Biopharmaceuticals, also referred to as biologics, belong to a category of pharmaceutical medications that originate from biological sources. These drugs are manufactured through biotechnological processes utilizing living organisms such as bacteria, yeast, or mammalian cells. In contrast to conventional small-molecule drugs synthesized chemically, biopharmaceuticals are characterized by their large and intricate molecular structures, which allow them to engage in highly precise interactions with biological targets within the body. Biopharmaceuticals offer numerous advantages over traditional pharmaceuticals. They often demonstrate a remarkable degree of specificity in their action, frequently targeting particular receptors or molecules. This specificity typically leads to enhanced effectiveness and a reduction in adverse side effects. Moreover, biopharmaceuticals hold the potential to treat diseases that were historically challenging to address using conventional drug approaches.

Japan Biopharmaceutical Market Trends:

In Japan, several factors are contributing to substantial market growth. Firstly, there is a notable surge in demand for personalized medicine, which is a significant driver. Additionally, the increased adoption of biopharmaceuticals for treating conditions such as cancer, diabetes, psoriasis, and rheumatoid arthritis is another key factor fueling this growth. Furthermore, there is a growing awareness among the general population regarding the effectiveness and accessibility of biopharmaceuticals, further propelling the regional market. Moreover, there is a heightened focus on addressing rare diseases and developing orphan drugs, which is driving market growth. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Besides this, governments and regulatory agencies have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions, which is acting as another significant growth-inducing factor. Furthermore, biopharmaceutical companies are actively investing in research and development (R&D) efforts to create orphan drugs targeting rare diseases. This approach not only addresses critical medical needs but also creates opportunities for expanding the market over the forecasted period.

Japan Biopharmaceutical Market Segmentation:

Indication Insights:

Autoimmune Diseases
Oncology
Metabolic Disorders
Others

Class Insights:

Recombinant Proteins
Monoclonal Antibodies
Purified Proteins

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan biopharmaceutical market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan biopharmaceutical market?
What is the breakup of the Japan biopharmaceutical market on the basis of indication?
What is the breakup of the Japan biopharmaceutical market on the basis of class?
What are the various stages in the value chain of the Japan biopharmaceutical market?
What are the key driving factors and challenges in the Japan biopharmaceutical?
What is the structure of the Japan biopharmaceutical market and who are the key players?
What is the degree of competition in the Japan biopharmaceutical market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biopharmaceutical Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biopharmaceutical Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Biopharmaceutical Market - Breakup by Indication

6.1 Autoimmune Diseases
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Oncology
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Metabolic Disorders
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Others
- 6.4.1 Historical and Current Market Trends (2019-2024)
- 6.4.2 Market Forecast (2025-2033)

7 Japan Biopharmaceutical Market - Breakup by Class

7.1 Recombinant Proteins
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Monoclonal Antibodies
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Purified Proteins
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)

8 Japan Biopharmaceutical Market - Competitive Landscape

8.1 Overview
8.2 Market Structure
8.3 Market Player Positioning
8.4 Top Winning Strategies
8.5 Competitive Dashboard
8.6 Company Evaluation Quadrant

9 Profiles of Key Players

9.1 Company A
- 9.1.1 Business Overview
- 9.1.2 Services Offered
- 9.1.3 Business Strategies
- 9.1.4 SWOT Analysis
- 9.1.5 Major News and Events
9.2 Company B
- 9.2.1 Business Overview
- 9.2.2 Services Offered
- 9.2.3 Business Strategies
- 9.2.4 SWOT Analysis
- 9.2.5 Major News and Events
9.3 Company C
- 9.3.1 Business Overview
- 9.3.2 Services Offered
- 9.3.3 Business Strategies
- 9.3.4 SWOT Analysis
- 9.3.5 Major News and Events
9.4 Company D
- 9.4.1 Business Overview
- 9.4.2 Services Offered
- 9.4.3 Business Strategies
- 9.4.4 SWOT Analysis
- 9.4.5 Major News and Events
9.5 Company E
- 9.5.1 Business Overview
- 9.5.2 Services Offered
- 9.5.3 Business Strategies
- 9.5.4 SWOT Analysis
- 9.5.5 Major News and Events

10 Japan Biopharmaceutical Market - Industry Analysis

10.1 Drivers, Restraints, and Opportunities
- 10.1.1 Overview
- 10.1.2 Drivers
- 10.1.3 Restraints
- 10.1.4 Opportunities
10.2 Porters Five Forces Analysis
- 10.2.1 Overview
- 10.2.2 Bargaining Power of Buyers
- 10.2.3 Bargaining Power of Suppliers
- 10.2.4 Degree of Competition
- 10.2.5 Threat of New Entrants
- 10.2.6 Threat of Substitutes
10.3 Value Chain Analysis